ClinicalTrials.gg

Program

REGN24493

A development code.

Its studies are mostly in Graves Disease, led by Regeneron Pharmaceuticals.

Furthest: phase 1, since Sep 30, 20261 company-led study, 1 open or runningNext primary completion: Jan 28, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals11 open or runningphase 1since Sep 30, 2026Sep 30, 2026Jan 28, 2030phase 1 · NCT07861152

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2026First study: phase 1 study in Graves DiseaseFirst studyNCT07861152 · 45 planned

Ahead

  1. Jan 28, 2030Primary completion: phase 1 study in Graves DiseaseNCT07861152

TargetBeta

TSHR →read by rule
“A Phase 1, Single-Ascending Dose Study of REGN24493, an Anti-TSHR Monoclonal Antibody, in Participants With Graves' Disease”study text, by rule · the study

Other programs on TSHR

ProgramCompanyFurthest phaseStudies
IBI3031ruleInnovent Biologicsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07861152Graves Disease1Not yet recruitingJan 28, 203045

How it is read

Names in the registry

  • “REGN24493”, 1 entry

Codes read as this program: REGN24493.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.